Form 4: UNITED THERAPEUTICS CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 13, 2026.

Summary

  • Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on July 13, 2026; holds 50,013 after (Direct).
  • Open-market sale: disposed of 1,020 Common Stock at $533.70 ($544,376) on July 13, 2026; holds 48,993 after (Direct).
  • Open-market sale: disposed of 2,272 Common Stock at $534.63 ($1,214,669) on July 13, 2026; holds 46,721 after (Direct).
  • Open-market sale: disposed of 2,191 Common Stock at $535.47 ($1,173,213) on July 13, 2026; holds 44,530 after (Direct).
  • Open-market sale: disposed of 2,223 Common Stock at $536.52 ($1,192,674) on July 13, 2026; holds 42,307 after (Direct).
  • Open-market sale: disposed of 665 Common Stock at $537.66 ($357,545) on July 13, 2026; holds 41,642 after (Direct).
  • Open-market sale: disposed of 409 Common Stock at $538.60 ($220,289) on July 13, 2026; holds 41,233 after (Direct).
  • Open-market sale: disposed of 320 Common Stock at $539.60 ($172,673) on July 13, 2026; holds 40,913 after (Direct).
  • Open-market sale: disposed of 360 Common Stock at $541.10 ($194,796) on July 13, 2026; holds 40,553 after (Direct).
  • Open-market sale: disposed of 40 Common Stock at $542.80 ($21,712) on July 13, 2026; holds 40,513 after (Direct).
  • Option exercise/conversion: disposed of 9,500 Stock Option on July 13, 2026; holds 11,218 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,091,949 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Martine A Rothblatt — Director, Officer (Chairperson & CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-07-13Option exercise/conversionCommon Stock9,500$135$1.3M50,013
2026-07-13Open-market saleCommon Stock1,020$534$544.4K48,993
2026-07-13Open-market saleCommon Stock2,272$535$1.2M46,721
2026-07-13Open-market saleCommon Stock2,191$535$1.2M44,530
2026-07-13Open-market saleCommon Stock2,223$537$1.2M42,307
2026-07-13Open-market saleCommon Stock665$538$357.5K41,642
2026-07-13Open-market saleCommon Stock409$539$220.3K41,233
2026-07-13Open-market saleCommon Stock320$540$172.7K40,913
2026-07-13Open-market saleCommon Stock360$541$194.8K40,553
2026-07-13Open-market saleCommon Stock40$543$21.7K40,513
2026-07-13Option exercise/conversionStock Option9,500——11,218

Key Dates

DateDescription
2026-07-13Option exercise/conversion (9,500 shares)
2026-07-13Open-market sale (1,020 shares)
2026-07-13Open-market sale (2,272 shares)
2026-07-13Open-market sale (2,191 shares)
2026-07-13Open-market sale (2,223 shares)
2026-07-13Open-market sale (665 shares)
2026-07-13Open-market sale (409 shares)
2026-07-13Open-market sale (320 shares)
2026-07-13Open-market sale (360 shares)
2026-07-13Open-market sale (40 shares)
2026-07-13Option exercise/conversion (9,500 shares)

Keywords

insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.